Candel Therapeutics, Inc.
CADL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | 0% | – |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | 100% | -11,575.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -13,046.4% | -20,395.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -15,035.2% | -28,899.2% |
| EPS Diluted | -1.74 | -1.31 | -0.099 | -1.26 |
| % Growth | -32.8% | -1,217.9% | 92.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |